Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.31 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.31 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6056234 | 1.00 | CYP1A2 (0.53) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL12021394 | 1.00 | CYP1A2 (0.53) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL6026034 | 1.00 | CYP1A2 (0.53) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL5388086 | 1.00 | CYP1A2 (0.53) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL2592513 | 1.00 | CYP1A2 (0.53) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL23355288 | 1.00 | CYP1A2 (0.53) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL3152370 | 1.00 | CYP1A2 (0.53) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL122049 | 1.00 | CYP1A2 (0.53) | CYP1A2USP2ALDH1A1LMNATSHR | |
| Hydrochloric Acid SCHEMBL6056323 | 0.98 | CYP1A2 (0.52) | CYP1A2USP2ALDH1A1LMNATSHR | |
| Hydrochloric Acid SCHEMBL5390370 | 0.98 | CYP1A2 (0.52) | CYP1A2USP2ALDH1A1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 269 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11471416-B2 | Extended release pharmaceutical formulation and methods of treatment | DOUGLAS PHARMACEUTICALS, LTD. (NZ) | 2022-10-18 | — | — | US | claimed |
| EP-2125021-B8 | COMBINATION THERAPY OF LOWER URINARY TRACT DISORDERS WITH ALPHA 2DELTA LIGANDS AND NSAIDS | RECORDATI IRELAND LTD (IE) | 2012-02-15 | — | — | EP | claimed |
| EP-2125021-B1 | COMBINATION THERAPY OF LOWER URINARY TRACT DISORDERS WITH 2 LIGANDS AND NSAIDS | RECORDATI IRELAND LTD (IE) | 2011-06-08 | — | — | EP | claimed |
| EP-2125021-A1 | COMBINATION THERAPY OF LOWER URINARY TRACT DISORDERS WITH 2 LIGANDS AND NSAIDS | Recordati Ireland Limited (IE) | 2009-12-02 | — | — | EP | claimed |
| US-20090036495-A1 | Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists | PFIZER, INC. | 2009-02-05 | — | — | US | claimed |
| WO-2008077599-A1 | COMBINATION THERAPY OF LOWER URINARY TRACT DISORDERS WITH α2δ LIGANDS AND NSAIDS | RECORDATI IRELAND LIMITED (IE) | 2008-07-03 | — | — | WO | claimed |
| US-20080153888-A1 | ALPHA-2-DELTA LIGAND/NSAID THERAPEUTIC TREATMENT OF LOWER URINARY TRACT DISORDERS | RECORDATI IRELAND LIMITED (IE) | 2008-06-26 | — | — | US | claimed |
| EP-1506955-B1 | Bicyclic amino acids as pharmaceuticals agents | WARNER LAMBERT CO (US) | 2007-03-28 | — | — | EP | claimed |
| EP-1658058-A1 | A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF ADDICTION IN A MAMMAL | Pfizer Products Inc. (US) | 2006-05-24 | — | — | EP | claimed |
| EP-1658098-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA2DELTA LIGAND AND AN OPIOID RECEPTOR ANTAGONIST FOR THE PREVENTION AND TREATMENT OF ADDICTION IN A MAMMAL | Pfizer Products Inc. (US) | 2006-05-24 | — | — | EP | claimed |
| EP-1357910-A2 | METHOD FOR PREVENTING AND TREATING VISCERAL PAIN AND GASTROINTESTINAL DISORDERS | Warner-Lambert Company LLC (US) | 2003-11-05 | — | — | EP | claimed |
| US-20030176504-A1 | Method of treating tinnitus | DOOLEY DAVID JAMES (US) | 2003-09-18 | — | — | US | claimed |
| WO-2003063845-A1 | ALPHA 2 DELTA LIGANDS TO TREAT TINNITUS | WARNER-LAMBERT COMPANY LLC (US) | 2003-08-07 | — | — | WO | claimed |
| US-20020161047-A1 | Method for preventing and treating visceral pain and gastrointestinal disorders | WARNER-LAMBERT COMPANY | 2002-10-31 | — | — | US | claimed |
| WO-2002058680-A2 | USE OF BICYLIC AMINO ACIDS FOR PREVENTING AND TREATING VISCERAL PAIN AND GASTROINTESTINAL DISORDERS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-01 | — | — | WO | claimed |
| EP-1226820-A1 | Use of bicyclic amino acids for preventing and treating visceral pain and gastrointestinal disorders | WARNER-LAMBERT COMPANY (US) | 2002-07-31 | — | — | EP | claimed |
| EP-1226110-A1 | BICYCLIC AMINO ACIDS AS PHARMACEUTICAL AGENTS | WARNER-LAMBERT COMPANY (US) | 2002-07-31 | — | — | EP | claimed |
| US-20020072533-A1 | Method of treating cartilage damage | SCHRIER DENIS (US) | 2002-06-13 | — | — | US | claimed |
| EP-1199072-A2 | Method of treating cartilage damage | WARNER-LAMBERT COMPANY (US) | 2002-04-24 | — | — | EP | claimed |
| WO-2001028978-A1 | BICYCLIC AMINO ACIDS AS PHARMACEUTICAL AGENTS | WARNER-LAMBERT COMPANY (US) | 2001-04-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176504-A1 | Method of treating tinnitus | ADRA2A, ADRA1A, ADRA1D | CYP1A2 483/4885USP2 3476/4885ALDH1A1 137/4885 |
| US-20020072533-A1 | Method of treating cartilage damage | COL2A1, COL1A1, GABRB1 | CYP1A2 1403/4885USP2 1071/4885ALDH1A1 30/4885 |
| US-11471416-B2 | Extended release pharmaceutical formulation and methods of treatment | CRH, HTR5A, NPY5R | CYP1A2 772/4885USP2 1206/4885ALDH1A1 2863/4885 |
| US-20020161047-A1 | Method for preventing and treating visceral pain and gastrointestinal disorders | ALPI, VIP, SLC10A2 | CYP1A2 845/4885USP2 3321/4885ALDH1A1 420/4885 |
| US-20090036495-A1 | Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists | PTGER4, PTGER2, OPRL1 | CYP1A2 1834/4885USP2 2450/4885ALDH1A1 1861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.